MitoQ is a brand owned by New Zealand Biotechnology Company, which is dedicated to helping people discover health and beauty over time.
MitoQ was registered by ANTIPODEAN PHARMACEUTICALS, Inc. in the United States in May 2003, and registered trademarks in New Zealand and Chinese mainland.
MitoQ's product line includes beauty series and health series, and its core patented technology-Mitoq molecule (mitochondrial targeted antioxidant) can slow down the oxidative stress damage of mitochondria and activate cell energy, thus supporting organ function and improving long-term health level.
MitoQ？ It is a great honor to cooperate with independent and non-interfering authoritative scientific research institutions to study MitoQ. Test supplement to understand MitoQ? Various benefits of supplements to human health. This important work not only verified the correlation between mitochondrial dysfunction and health, but also confirmed MitoQ? Is beneficial to supporting cells, organs and health. ?
MitoQ is a mitochondrial targeted antioxidant, which can repair the oxidative damage of mitochondria in cells. ?
The research team led by the University of Colorado at Boulder reported in the new issue of the American Journal of Hypertension that they selected 20 healthy men and women aged between 60 and 79 as the research objects, half of whom took 20mg of Mitok supplement every day, and the other half took a placebo as a control.
Six weeks later, the researchers measured the degree of arterial dilation and changes in blood flow, and evaluated the function of their vascular endothelial cells. After that, the subjects went through a "cleaning" period without taking any supplements for two weeks, and the researchers switched the two groups of subjects and re-tested them.
The results showed that after taking MitoQ supplement, the arterial dilation rate of the subjects increased by 42%, making their blood vessels at least "young" 15 to 20 years old. The researchers pointed out that if this situation can be continuously improved, the incidence of heart disease can be reduced by about 13%. ?
"This is the first clinical trial to evaluate the effect of antioxidants targeting mitochondria on human vascular function," said Matthew Rothman, the lead author of the study. "This suggests that similar therapy may help reduce the risk of age-related cardiovascular disease."
The above contents refer to Baidu Encyclopedia -MitoQ.